Viking Global Opportunities Parent GP LLC
Insider CIK 1886738 · PRCT 10% owner · ROIV 10% owner · FDMT 10% owner · AMLX 10% owner · RLYB 10% owner · INBX 10% owner · BBIO 10% owner · APG 10% owner · RYZB 10% owner · FLAC 10% owner · DNA 10% owner · INBX 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences, Inc. | S Sale | 2025-10-07 | 2025-10-09 | 25,042 | $32.25 | $807.6K | 102,864 | SEC↗ |
| INBX Inhibrx Biosciences, Inc. | S Sale | 2025-10-07 | 2025-10-09 | 308,643 | $32.25 | $9.95M | 1,267,823 | SEC↗ |
| INBX Inhibrx Biosciences, Inc. | S Sale | 2025-10-07 | 2025-10-09 | 16,315 | $32.25 | $526.2K | 67,018 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2025-06-27 | 2025-07-01 | 3,500,000 | $44.00 | $154.00M | 18,555,375 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2025-01-31 | 2025-01-31 | 3,065,616 | $34.90 | $106.99M | 22,055,375 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-06-17 | 2024-06-18 | 1,912,750 | $38.15 | $72.97M | 0 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-06-17 | 2024-06-18 | 39,032 | $38.15 | $1.49M | 0 | SEC↗ |
| INBX Inhibrx, Inc. | J Other deriv | 2024-05-30 | 2024-06-03 | 1,038,765 | $30.00 | $31.16M | 0 | SEC↗ |
| INBX Inhibrx, Inc. | J Other | 2024-05-30 | 2024-06-03 | 511,627 | $30.00 | $15.35M | 0 | SEC↗ |
| INBX Inhibrx, Inc. | J Other | 2024-05-30 | 2024-06-03 | 333,333 | $30.00 | $10.00M | 0 | SEC↗ |
| INBX Inhibrx, Inc. | J Other | 2024-05-30 | 2024-06-03 | 6,305,866 | $30.00 | $189.18M | 0 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-03-05 | 2024-03-07 | 2,977,845 | $34.25 | $101.99M | 1,912,750 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-03-05 | 2024-03-07 | 60,772 | $34.25 | $2.08M | 39,032 | SEC↗ |
| APG APi Group Corp | C Conversion deriv | 2024-02-28 | 2024-03-01 | 4,000 | — | $0 | 0 | SEC↗ |
| APG APi Group Corp | C Conversion deriv | 2024-02-28 | 2024-03-01 | 196,000 | — | $0 | 0 | SEC↗ |
| APG APi Group Corp | J Other | 2024-02-28 | 2024-03-01 | 81,300 | $36.90 | $3.00M | 99,804 | SEC↗ |
| APG APi Group Corp | J Other | 2024-02-28 | 2024-03-01 | 3,983,739 | $36.90 | $147.00M | 4,890,595 | SEC↗ |
| APG APi Group Corp | C Conversion | 2024-02-28 | 2024-03-01 | 164,016 | $24.60 | $4.03M | 181,104 | SEC↗ |
| APG APi Group Corp | C Conversion | 2024-02-28 | 2024-03-01 | 8,036,862 | $24.60 | $197.71M | 8,874,334 | SEC↗ |
| RYZB RayzeBio, Inc. | J Other | 2024-02-26 | 2024-02-28 | 1,743,556 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | J Other | 2024-02-26 | 2024-02-28 | 4,899,144 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | J Other | 2024-02-26 | 2024-02-28 | 4,899,144 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | J Other | 2024-02-26 | 2024-02-28 | 1,743,556 | — | $0 | 0 | SEC↗ |
| FDMT 4D Molecular Therapeutics, | S Sale | 2024-01-04 | 2024-01-05 | 540,000 | $19.53 | $10.55M | 4,247,914 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-01-02 | 2024-01-04 | 6,300,817 | $31.30 | $197.22M | 27,032,516 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-01-02 | 2024-01-04 | 195,200 | $31.30 | $6.11M | 837,472 | SEC↗ |
| APG APi Group Corp | S Sale | 2024-01-02 | 2024-01-04 | 3,983 | $31.30 | $124.7K | 17,088 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 432,254 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 432,254 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion deriv | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 3,968,588 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 1,285,223 | SEC↗ |
| RYZB RayzeBio, Inc. | P Buy | 2023-09-19 | 2023-09-21 | 930,556 | $18.00 | $16.75M | 4,899,144 | SEC↗ |
| RYZB RayzeBio, Inc. | P Buy | 2023-09-19 | 2023-09-21 | 458,333 | $18.00 | $8.25M | 1,743,556 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 494,687 | — | $0 | 1,359,196 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 864,509 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 494,687 | — | $0 | 1,359,196 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 1,285,223 | — | $0 | 1,285,223 | SEC↗ |
| RYZB RayzeBio, Inc. | P Buy | 2023-09-19 | 2023-09-21 | 458,333 | $18.00 | $8.25M | 1,743,556 | SEC↗ |
| RYZB RayzeBio, Inc. | P Buy | 2023-09-19 | 2023-09-21 | 930,556 | $18.00 | $16.75M | 4,899,144 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 2,609,392 | — | $0 | 3,968,588 | SEC↗ |
| RYZB RayzeBio, Inc. | C Conversion | 2023-09-19 | 2023-09-21 | 864,509 | — | $0 | 864,509 | SEC↗ |
| INBX Inhibrx, Inc. | P Buy deriv | 2023-08-28 | 2023-08-30 | 1,038,765 | $19.35 | $20.10M | 1,038,765 | SEC↗ |
| INBX Inhibrx, Inc. | P Buy | 2023-08-28 | 2023-08-30 | 511,627 | $19.35 | $9.90M | 511,627 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | S Sale | 2023-07-18 | 2023-07-19 | 1,500,000 | $35.00 | $52.50M | 25,120,991 | SEC↗ |
| ROIV Roivant Sciences Ltd. | S Sale | 2023-06-22 | 2023-06-26 | 5,427,043 | $9.90 | $53.73M | 31,409,512 | SEC↗ |
| ROIV Roivant Sciences Ltd. | S Sale | 2023-06-22 | 2023-06-26 | 5,236,006 | $9.90 | $51.84M | 30,303,871 | SEC↗ |
| ROIV Roivant Sciences Ltd. | S Sale | 2023-06-22 | 2023-06-26 | 2,226,195 | $9.90 | $22.04M | 12,884,307 | SEC↗ |
| ROIV Roivant Sciences Ltd. | S Sale | 2023-06-22 | 2023-06-26 | 110,756 | $9.90 | $1.10M | 641,010 | SEC↗ |
| FDMT 4D Molecular Therapeutics, | P Buy | 2023-05-09 | 2023-05-11 | 850,000 | $16.00 | $13.60M | 4,787,914 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | C Conversion | 2022-11-22 | 2022-11-25 | 2,459,880 | — | $0 | 0 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | C Conversion | 2022-11-22 | 2022-11-25 | 1,211,582 | — | $0 | 0 | SEC↗ |
| RLYB Rallybio Corp | P Buy deriv | 2022-11-15 | 2022-11-17 | 3,333,388 | $6.00 | $20.00M | 3,333,388 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | C Conversion deriv | 2022-11-11 | 2022-01-13 | 4,870,536 | — | $0 | 0 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | P Buy | 2022-11-02 | 2022-11-04 | 279,530 | $10.08 | $2.82M | 1,211,582 | SEC↗ |
| FLAC Frazier Lifesciences Acqui | P Buy | 2022-11-02 | 2022-11-04 | 567,532 | $10.08 | $5.72M | 2,459,880 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 3,142 | $31.44 | $98.8K | 1,850,940 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 73,886 | $30.90 | $2.28M | 1,854,082 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 147,502 | $29.87 | $4.41M | 1,927,968 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 6,654 | $31.44 | $209.2K | 3,919,596 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 156,463 | $30.90 | $4.83M | 3,926,250 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-09 | 2022-09-09 | 312,353 | $29.87 | $9.33M | 4,082,713 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 108,631 | $28.16 | $3.06M | 4,681,190 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 80,715 | $27.28 | $2.20M | 4,789,821 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 159,026 | $29.14 | $4.63M | 4,522,164 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 52,466 | $32.23 | $1.69M | 2,075,470 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 7,554 | $30.59 | $231.1K | 2,127,936 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 75,096 | $29.14 | $2.19M | 2,135,490 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 51,298 | $28.16 | $1.44M | 2,210,586 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 38,116 | $27.28 | $1.04M | 2,261,884 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 111,102 | $32.23 | $3.58M | 4,395,066 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | S Sale | 2022-09-08 | 2022-09-09 | 15,996 | $30.59 | $489.3K | 4,506,168 | SEC↗ |
| PRCT PROCEPT BioRobotics Corp | S Sale | 2022-03-18 | 2022-03-22 | 101,795 | $29.90 | $3.04M | 298,205 | SEC↗ |
| PRCT PROCEPT BioRobotics Corp | S Sale | 2022-03-18 | 2022-03-22 | 1,147,205 | $29.90 | $34.30M | 3,360,687 | SEC↗ |
| DNA Ginkgo Bioworks Holdings, | J Other deriv | 2022-03-02 | 2022-03-04 | 288,000,000 | — | $0 | 288,000,000 | SEC↗ |
| DNA Ginkgo Bioworks Holdings, | J Other | 2022-03-02 | 2022-03-04 | 288,000,000 | — | $0 | 51,055,144 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | C Conversion | 2022-01-11 | 2022-01-13 | 4,870,536 | — | $0 | 4,870,536 | SEC↗ |
| AMLX Amylyx Pharmaceuticals, In | P Buy | 2022-01-11 | 2022-01-13 | 2,300,000 | $19.00 | $43.70M | 2,300,000 | SEC↗ |